As a member of the senior leadership team in AstraZeneca’s Innovative Medicines & Early Development Biotech Unit, I am accountable for delivering diagnostics across AstraZeneca’s R&D pipeline to match targeted medicines to those patients most likely to benefit. I also lead AstraZeneca/ MedImmune’s Genomics Initiative, which aims to transform drug discovery and development by analysing up to 2 million genomes. I have led the development of AstraZeneca’s industry-leading capability in precision medicine, with 16 diagnostics launched linked to 4 AstraZeneca medicines since 2014. Precision medicine is now applied in >90% of AstraZeneca’s clinical pipeline across all main therapy areas - oncology, CVMD, and respiratory disease. I have also led an innovative approach to diagnostics, developing technologies that best fit the patient’s care pathway. In addition, I have led over $185M investment with diagnostic partners, including molecular diagnostics, tissue diagnostics, next generation sequencing and point of care diagnostics.

Innovative Medicines & Early Development Biotech